SCHEMBL7216335

SCHEMBL7216335

COc1ccccc1COc1ccc2c(c1)C=C(C(=O)O)CCS2(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 3/20 0.45
PARP14 Q460N5 1/20 0.45
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ALKBH1 Q13686 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.39
PARP15 Q460N3 2/20 0.39
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ATM Q13315 1/20 0.38
PTGER4 P35408 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SPHK2 Q9NRA0 2/20 0.38
SPHK1 Q9NYA1 2/20 0.38
HRH3 Q9Y5N1 2/20 0.37
LNPEP Q9UIQ6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7216128 0.91 PARP10 (0.44) PARP10PARP14MEN1KMT2AL3MBTL1
SCHEMBL7217018 0.91 PARP14 (0.36) PARP10PARP14L3MBTL1ALDH1A1NPC1
SCHEMBL7215840 0.89 PPARD (0.37) PARP10PARP14KMT2AL3MBTL1KDM4E
SCHEMBL7218231 0.87 MAPT (0.34) PARP10PARP14MEN1KMT2AL3MBTL1
SCHEMBL7216783 0.86 PPARD (0.35) PARP10PARP14MEN1KMT2AL3MBTL1
SCHEMBL7218103 0.86 NR4A2 (0.49) MEN1KMT2AALKBH1NPC1RAB9A
SCHEMBL7218091 0.83 PARP10 (0.37) PARP10PARP14MEN1KMT2AL3MBTL1
SCHEMBL7216431 0.82 MRGPRX4 (0.50) ALKBH1NPC1RAB9ASMN1; SMN2MRGPRX4
SCHEMBL7222714 0.81 FFAR4 (0.32)
SCHEMBL7216417 0.81 PPARD (0.42) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed